van den Nieuwendijk Adrianus M C H, Pietra Daniele, Heitman Laura, Göblyös Anikó, IJzerman Adriaan P
Leiden/Amsterdam Center for Drug Research, Division of Medicinal Chemistry, Leiden University, P.O. Box 9502, 2300RA Leiden, The Netherlands.
J Med Chem. 2004 Jan 29;47(3):663-72. doi: 10.1021/jm030863d.
A number of 2,3,5-substituted [1,2,4]thiadiazole analogues of SCH-202676 (N-(2,3-diphenyl[1,2,4]thiadiazole-5(2H)-ylidene)methanamine, 7a) were synthesized and tested as potential allosteric modulators of adenosine receptors. All compounds were capable of displacing the binding of the radiolabeled agonist [(3)H]CCPA to human A(1) adenosine receptors, whereas modest and varying effects were observed on the binding of [(3)H]DPCPX, a radiolabeled antagonist for this receptor subtype. Four compounds, 7a (SCH-202676), 7k (LUF5792), 7l (LUF5794), and 8e (LUF5789), were selected for more detailed characterization. They all proved allosteric inhibitors of agonist binding, with 7k being most potent, whereas their effects on antagonist binding were more ambiguous. Subsequently, experiments were done on human adenosine A(2A) and A(3) receptors. Compounds 7a and 7l displayed peculiar displacement characteristics of both radiolabeled agonist and antagonist binding to A(2A) receptors, whereas 7a showed some activity on A(3) receptors.
合成了一系列SCH-202676(N-(2,3-二苯基[1,2,4]噻二唑-5(2H)-基亚甲基)甲胺,7a)的2,3,5-取代[1,2,4]噻二唑类似物,并作为腺苷受体的潜在变构调节剂进行了测试。所有化合物都能够取代放射性标记激动剂[(3)H]CCPA与人A(1)腺苷受体的结合,而对于该受体亚型的放射性标记拮抗剂[(3)H]DPCPX的结合则观察到适度且不同的影响。选择了四种化合物,7a(SCH-202676)、7k(LUF5792)、7l(LUF5794)和8e(LUF5789)进行更详细的表征。它们都被证明是激动剂结合的变构抑制剂,其中7k最有效,而它们对拮抗剂结合的影响则更为模糊。随后,对人腺苷A(2A)和A(3)受体进行了实验。化合物7a和7l对放射性标记激动剂和拮抗剂与A(2A)受体的结合均表现出独特的取代特征,而7a对A(3)受体显示出一定活性。